Quoin Pharmaceuticals Says US FDA Clears Phase 2 Trial of QRX003 in Peeling Skin Syndrome
() -- Quoin Pharmaceuticals (QNRX) said Thursday the US Food and Drug Administration has cleared its planned phase 2 clinical trial of QRX003 to potentially treat peeling skin syndrome. The company said it expects to initiate the study in H2 and plans to enroll six to eight pediatric and adult patients in the US and Eu